AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1636921
Drug: Tramadol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol infusion (400 mg tramadol plus 10 ml placebo in 500 ml electrolyte solution) with ibuprofen suppositories (585.2 mg) preoperatively
Trial: 1636921
Drug: Tramadol and
RxNorm normalized name: tramadol and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol and metamizole infusion
Trial: 1636921
Drug: Tramadol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol infusion with ibuprofen suppositories
Trial: 31187102
Drug: 30 mg/mL
RxNorm normalized name: urea 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/mL ketorolac tromethamine
Trial: 27144937
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 20 mg thrice daily for 4 weeks
Trial: 2920584
Drug: Methylprednisolone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (100 mg)
Trial: 27189038
Drug: Treatment arms
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arms comparison
Trial: 25881614
Drug: DRV/r once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r once-daily (800/100 mg)
Trial: 25881614
Drug: DRV/r twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r twice-daily (600/100 mg)
Trial: 23809446
Drug: 12.0‐μg/h fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.0‐μg/h fentanyl patch for 72 hours
Trial: 23809446
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch and an infusion of 2.5‐mg/mL bupivacaine in a subacromial manner for 72 hours
Trial: 8561982
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine trial participation
Trial: 350264
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atenolol and adrenaline
Trial: 30921609
Drug: Transcranial alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial alternating current stimulation (tACS) at 4 Hz or 30 Hz based on EEG analysis, 5 days/week for 2 weeks followed by physical therapy.
Trial: 26152940
Drug: Ophthalmic solution
RxNorm normalized name: Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution containing an allergen (CPT)
Trial: 23550857
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg sublingual misoprostol
Trial: 19249425
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus coumarin (adjunctive anticoagulation)
Trial: 15492433
Drug: Benzoyl peroxide-erythromycin
RxNorm normalized name: Benzoyl Peroxide-Erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide-erythromycin gel
Trial: 3207549
Drug: Bilateral ilioinguinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ilioinguinal nerve blockade using 0.5% plain bupivacaine 10 ml to each side
Trial: 29427701
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day; n=20)
Trial: 29427701
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg/day; n=20)
Trial: 18156881
Drug: Lower tidal
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower tidal volumes of 6 ml/kg and 10 cm H2O PEEP
Trial: 18156881
Drug: Higher tidal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure (PEEP)
Trial: 15696037
Drug: Contrast-enhanced ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound scanning (CUS) with a bolus of 1.5 to 2.4 mL of a second generation blood pool contrast agent
Trial: 11796347
Drug: Ruprintrivir (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruprintrivir (4 mg single dose)
Trial: 11796347
Drug: Ruprintrivir (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruprintrivir (8 mg single dose)
Trial: 11796347
Drug: Ruprintrivir (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruprintrivir (multiple doses every 3 h, six times per day for 7 days)
Trial: 10363622
Drug: Caudal tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal tramadol (1 mg/kg)
Trial: 10363622
Drug: 0.25% plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% plain bupivacaine (0.5 ml/kg)
Trial: 3422243
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine solution
Trial: 31927518
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and written education using aspirin booklet
Trial: 26727825
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab 1.25 mg/0.05 mL (Avastin)
Trial: 26727825
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of triamcinolone acetonid 4 mg/0.1 mL (Kenalog)
Trial: 23460711
Drug: Fluorouracil (FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FU) ‐based chemotherapy with irinotecan (IRI)
Trial: 19375557
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) with antiglycemic medications
Trial: 17298589
Drug: Nateglinide +
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide + insulin glargine
Trial: 17298589
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + insulin glargine
Trial: 11377114
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment sooner
Trial: 3893389
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion when COP fell below 24 cm H2O
Trial: 3893389
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion when COP fell below 29 cm H2O
Trial: 25352870
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment guidelines (STG) intervention group
Trial: 23600305
Drug: Proton-photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-photon therapy with proton beam 220Mev, focal dose of 28-28.8 Gy-eq for 8, 5 or 3 fractions (3, 4 or 5.5 Gy-eq)
Trial: 23600305
Drug: Proton-photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-photon therapy
Trial: 18627368
Drug: Interrupted sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interrupted sevoflurane administration (SevoI)
Trial: 18627368
Drug: Continuous sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous sevoflurane administration (SevoC)
Trial: 10451167
Drug: Loperamide (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d) plus Oral Rehydration Therapy (ORT) (500 mL initially, followed by 250 mL after each subsequently passed unformed stool, up to 1,000 mL per 24 hours)
Trial: 10451167
Drug: Loperamide (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d)
Trial: 7575286
Drug: Topical antifungals
RxNorm normalized name: Imidazole and triazole derivatives, topical antifungals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antifungals (nystatin and amphotericin B suspensions)
Trial: 30302465
Drug: Ubiquinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (200 mg d‐1)
Trial: 30302465
Drug: Ubiquinone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinone (200 mg d‐1)
Trial: 22795238
Drug: Intra-articular contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular contrast injection only
Trial: 15591082
Drug: Viscoelastic gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscoelastic gel
Trial: 8890060
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (debridement only)
Trial: 1503621
Drug: Sequential immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential immunosuppressive therapy (alternative therapy after no or minimal response)
Trial: 6366617
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (50 mg every three weeks for two years)
Trial: 17368095
Drug: Glutamate injection
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injection
Trial: 24237929
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem cream
Trial: 19708174
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy throughout pregnancy
Trial: 19708174
Drug: No metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No metformin therapy throughout pregnancy (Control)
Trial: 17977295
Drug: Daily topical
RxNorm normalized name: Clindagel 1 % Once-Daily Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical applications of a dental cream containing CPP‐ACP (Topacal) for 3 months followed by a 3‐month period of daily toothbrushing with fluoridated dentifrice.
Trial: 17977295
Drug: Daily 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 0.05% sodium fluoride mouthwash combined with fluoridated dentifrice for 6 months.
Trial: 15903281
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no supplementary medication)
Trial: 12553505
Drug: Indomethacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (2 x 50 mg a day)
Trial: 1198015
Drug: Stellate ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate ganglion block with 10 ml of 0.5% Marcaine
Trial: 1198015
Drug: Intra articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra articular hydrocortisone injection (50 mg of hydrocortisone acetate into the glenohumeral joint)
Trial: 30095747
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 0
Trial: 30095747
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels across all days
Trial: 30095747
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 2
Trial: 30095747
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 1
Trial: 30095747
Drug: Plasma interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels
Trial: 28962661
Drug: Cinnamomum zeylanicum
RxNorm normalized name: Cinnamomum camphora resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamomum zeylanicum extract (250 mg)
Trial: 28962661
Drug: Cinnamomum zeylanicum
RxNorm normalized name: Cinnamomum camphora resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamomum zeylanicum extract (500 mg)
Trial: 26383034
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and minimal nontraditional acupuncture (minimally active penetrating)
Trial: 15871313
Drug: Topical eutectic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eutectic mixture of local anesthetics (EMLA)
Trial: 15871313
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (LMX)
Trial: 12587324
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nebivolol and enap
Trial: 7037505
Drug: Nine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine daily injections of fast‐acting insulin for ten days (group B)
Trial: 7037505
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with one or two daily doses of insulin (group A)
Trial: 24331115
Drug: DHEA 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 75 mg daily for 12 weeks
Trial: 15455733
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg B.I.D. with scaling and root planing (SRP)
Trial: 11306234
Drug: BV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BV treatment in high-risk women (previous preterm delivery)
Trial: 11306234
Drug: BV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BV treatment in high-risk women (not having BV)
Trial: 11306234
Drug: Routine BV
RxNorm normalized name: Bifidobacterium longum bv. infantis whole
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine BV screening and treatment
Trial: 811237
Drug: Intramuscular and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular and oral bromhexine for 5 days
Trial: 811237
Drug: Intramuscular and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular and oral bromhexine for 5 days in high-risk patients
Trial: 25331270
Drug: Red Bull
RxNorm normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Bull Energy drink (caffeine at 2 mg/kg body weight)
Trial: 21712623
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no APF gel application)
Trial: 19350335
Drug: Ponseti treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponseti treatment group
Trial: 16689810
Drug: Alcohol-based gels
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol-based gels with varying glycerine concentrations and alcohol grades (70% ethanol)
Trial: 16689810
Drug: Isopropanol-based gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropanol-based gel
Trial: 7905376
Drug: Levocabastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine eye drops (0.5 mg/ml) given from twice to four times daily for 1-8 weeks
Trial: 7905376
Drug: Levocabastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine eye drops (0.5 mg/ml)
Trial: 3066142
Drug: Nimodipine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (intravenous treatment)
Trial: 23106907
Drug: Standardized physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physiotherapy protocol (mask with positive expiratory pressure of 10 cm H2O, expiratory rib cage compression, coughing, lifting upper limbs, ambulation, starting within 4 hours post-surgery, 3 times daily)
Trial: 22017069
Drug: Calcipotriene 0.005%-betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment with hydrogel patch
Trial: 22017069
Drug: Calcipotriene 0.005%-betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment without hydrogel patch
Trial: 18435781
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (Exubera, EXU) with standard care
Trial: 9688485
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of cefuroxime intravenously at cord clamping (n = 59)
Trial: 25124964
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group using 'TOPHAT655' unit with 21, 5 mW diode lasers (655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments, 67 J/cm² irradiance, 25 minute treatment, 2.9 J dose).
Trial: 25124964
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment group using an identical unit containing incandescent red lights.
Trial: 17488308
Drug: Vardenafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (10 mg for 4 weeks, titrated to preferred dose of 5, 10, or 20 mg during the next 8 weeks, maintained at preferred dose for 14 weeks)
Trial: 9678530
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.1 IU/kg s.c.)
Trial: 2729170
Drug: Aspartame (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (10 mg aspartame/kg)
Trial: 29720202
Drug: Standard acquisition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard acquisition parameters with double dose (0.2 mmol/kg) Gadovist and 4 mm slice thickness.
Trial: 29720202
Drug: Reduced, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced, single dose of GBCA (n=10), half slice thickness (n=10), or on a 3T scanner (n=10).
Trial: 28705252
Drug: PGx-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGx-guided treatment (n=155)
Trial: 28705252
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU, control group, n=161)
Trial: 26179186
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with defibrillator
Trial: 24119702
Drug: Probiotics (Golden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Golden Bifid, 3.5 g for 3 times per day) for 21 days
Trial: 24119702
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional treatment and enteral nutrition)
Trial: 20363036
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments delivered to patients
Trial: 20363036
Drug: Therapeutic trials
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic trials with chemotherapy agents
Trial: 12233984
Drug: Contingent monetary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingent monetary reinforcement (CM) combined with 21 mg transdermal nicotine
Trial: 12233984
Drug: Contingent monetary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingent monetary reinforcement (CM) combined with placebo patch
Trial: 12233984
Drug: Noncontingent reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontingent reinforcement combined with placebo patch
Trial: 7501142
Drug: Overall surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall surgical therapy
Trial: 2176948
Drug: Control (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (in vitro measurement without drug)
Trial: 23581720
Drug: B-LAL (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily, bismuth potassium citrate 220 mg b.i.d. for 14 days)
Trial: 23581720
Drug: LAL (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily for 14 days)
Trial: 20581422
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of dialysis (when estimated GFR was 10.0 to 14.0 ml per minute)
Trial: 20581422
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of dialysis (when estimated GFR was 5.0 to 7.0 ml per minute)
Trial: 18430999
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (10, 20, 40, or 60 IU)
Trial: 2961356
Drug: Oral Cl2MDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cl2MDP (1600 mg twice daily for 16 weeks)